Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  SciClone Pharmaceuticals, Inc.    SCLN

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SciClone to Restate Results for Certain Periods on China Accounting Errors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 11:05pm CEST
   By Debbie Cai 
 

SciClone Pharmaceuticals Inc. (>> SciClone Pharmaceuticals, Inc.) said it will restate its financial statements for certain periods in 2012 and 2011 due mainly to accounting errors at a Chinese subsidiary.

Shares slid 6.2% to $4.52 after hours Friday. The stock is up 12% so far this year.

Chinese drugmaker NovaMed Pharmaceuticals Inc., which SciClone acquired in April 2011, made accounting errors pertaining to the timing of Pfizer Inc. (>> Pfizer Inc.) product-revenue recognition and the recognition of product-return reserves as to antiplatelet drug Aggrastat.

The company will restate financial statements for the first, second and third quarters of last year, the second and third quarters of 2011, and for the full 2011.

SciClone Chief Executive Friedhelm Blobel said the decision to restate financials, which is expected to increase the company's 2012 revenue and earnings and decrease that of 2011, was made after careful review of available facts.

The company believes the changes will raise its revenue for the first nine months of last year by about $3 million, and increase its profit before income taxes by about $2 million. The changes for the full 2011 will lower revenue by about $1 million and decrease income by less than $1 million.

SciClone also said the goodwill related to the acquisition of NovaMed will be increased by approximately $2 million. The restatements wouldn't impact previously reported cash or cash equivalents balances, the company said.

The company said it plans to amend its 2011 10-K form and other relevant filings as soon as reasonably practicable.

Last November, SciClone said it swung to a third-quarter loss as the company works to address issues across its China organization, some of which might have affected sales of its lead drug Zadaxin.

Write to Debbie Cai at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SciClone Pharmaceuticals, Inc., Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SCICLONE PHARMACEUTICALS,
08/29 Levi & Korsinsky, LLP Notifies Shareholders of SciClone Pharmaceuticals, Inc...
08/29 SCICLONE PHARMACEUTICALS : Corporate News Blog - Novo Nordisk’s Victoza(R)..
08/17 Monteverde & Associates PC Announces An Investigation Of SciClone Pharmaceuti..
08/17 SCICLONE PHARMACEUTICALS : Patent Issued for Treatment of Cancer with Immune Sti..
08/16 SCICLONE PHARMACEUTICALS : Breakfast Technical Briefing on Drug Makers Stocks --..
08/11 SCICLONE PHARMACEUTICALS : Reports Second Quarter 2017 Financial Results
08/11 SCICLONE PHARMACEUTICALS : Announces End of Go - Shop Period With No Parties Des..
08/10 SCICLONE PHARMACEUTICALS, INC. (NASD : SCLN) Files An 8-K Financial Statements a..
08/10 SCICLONE PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (..
08/10 SCICLONE PHARMACEUTICALS : Announces End Of Go-Shop Period With No Parties Desig..
More news
News from SeekingAlpha
08/09 SciClone Pharmaceuticals beats by $0.06, beats on revenue
06/09 RISK ARBITRAGE TODAY : Yahoo, Pandora And An M&A Fund That Has 20% In One Stock
06/08 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/08 PREMARKET GAINERS AS OF 9 : 05 am
06/08 SciClone Pharma to be acquired by Chinese consortium for $605M; shares up 7% ..
Financials ($)
Sales 2017 174 M
EBIT 2017 51,1 M
Net income 2017 49,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 11,81
P/E ratio 2018 10,37
Capi. / Sales 2017 3,33x
Capi. / Sales 2018 3,12x
Capitalization 579 M
Chart SCICLONE PHARMACEUTICALS,
Duration : Period :
SciClone Pharmaceuticals,  Technical Analysis Chart | SCLN | US80862K1043 | 4-Traders
Technical analysis trends SCICLONE PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 14,0 $
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Friedhelm Blobel President, Chief Executive Officer & Director
Jon Sheldon Saxe Chairman
Wai-Shun Cheung Chief Financial Officer & Senior VP-Finance
Richard J. Hawkins Independent Director
Gregg Anthony Lapointe Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SCICLONE PHARMACEUTICALS, INC.3.24%579
JOHNSON & JOHNSON15.63%352 651
NOVARTIS11.88%224 990
ROCHE HOLDING LTD.6.19%220 358
PFIZER10.81%214 146
MERCK AND COMPANY11.75%177 633